- Conditions
- Genetic Testing, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Colorectal Cancer, Renal Cancer, Melanoma, Sarcoma
- Interventions
- Video Education, Genetic Counseling
- Behavioral
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,334 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1609–1632
of 2,274
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer
- Interventions
- Taxotere (Docetaxel), Alimta (Pemetrexed)
- Drug
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2014
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Ovarian Cancer
- Interventions
- Acalabrutinib, acalabrutinib and pembrolizumab combination
- Drug
- Lead sponsor
- Acerta Pharma BV
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 2
- States / cities
- Tucson, Arizona • Philadelphia, Pennsylvania
- Conditions
- Fallopian Tube Cancer, Female Reproductive Cancer, Ovarian Carcinosarcoma, Ovarian Sarcoma, Recurrent Ovarian Epithelial Cancer, Recurrent Uterine Sarcoma, Stage III Ovarian Epithelial Cancer, Stage III Uterine Sarcoma, Stage IV Ovarian Epithelial Cancer, Stage IV Uterine Sarcoma, Uterine Carcinosarcoma, Uterine Leiomyosarcoma
- Interventions
- ziv-aflibercept
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 8
- States / cities
- Duarte, California • Los Angeles, California • Sacramento, California + 5 more
- Conditions
- Cancer
- Interventions
- recombinant interleukin-12
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Premature Ovarian Failure
- Interventions
- Estradiol/Medroxyprogesterone acetate
- Drug
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- 18 Years to 40 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, High-grade Serous Ovarian Cancer, Endometrioid Ovarian Cancer, Ovarian Clear Cell Carcinoma
- Interventions
- olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin (preferred) or cisplatin, Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin, Bevacizumab (or biosimilar)
- Biological · Drug
- Lead sponsor
- Genelux Corporation
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 33
- States / cities
- Mobile, Alabama • Tucson, Arizona • Duarte, California + 28 more
- Conditions
- Ovarian Epithelial Cancer Stage I, Ovarian Epithelial Cancer Stage II, Ovarian Epithelial Cancer Stage III, Stage I Fallopian Tube Cancer, Stage II Fallopian Tube Cancer, Stage III Fallopian Tube Cancer, Peritoneal Carcinoma
- Interventions
- Second look laparoscopy reassessment surgery (SLLRS), HIPEC with Carboplatin, FACT-O Quality of Life Questionnaire
- Procedure · Drug · Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Colorectal Carcinoma, Endometrial Carcinoma, Melanoma, Neuroblastoma, Ovarian Carcinoma, Pancreatic Ductal Adenocarcinoma, Recurrent Desmoid Fibromatosis, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Hepatocellular Carcinoma, Recurrent Malignant Solid Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Refractory Desmoid Fibromatosis, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Hepatocellular Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Solid Pseudopapillary Neoplasm of the Pancreas, Wilms Tumor
- Interventions
- Biospecimen Collection, Dual X-ray Absorptiometry, Tegavivint, X-Ray Imaging
- Procedure · Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 12 Months to 30 Years
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Los Angeles, California • Orange, California + 18 more
- Conditions
- Ovarian Cancer, TNBC, SCLC, Other Solid Tumours
- Interventions
- AZD 1775
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 13
- States / cities
- Fayetteville, Arkansas • San Francisco, California • West Hollywood, California + 10 more
- Conditions
- Ovarian Neoplasms, Ascites
- Interventions
- aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Breast Cancer, Leukemia, Lymphoma, Neuroblastoma, Ovarian Cancer, Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- filgrastim, amifostine trihydrate, cyclophosphamide, melphalan, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- University of Kentucky
- Other
- Eligibility
- 14 Years to 70 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 4
- States / cities
- Lexington, Kentucky • Baltimore, Maryland • Philadelphia, Pennsylvania + 1 more
- Conditions
- Ovarian Tumor
- Interventions
- ADNEXMR SCORING system
- Other
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Interventions
- Nemvaleukin and Pembrolizumab Combination, Pembrolizumab, Nemvaleukin, Pegylated Liposomal Doxorubicin (PLD), Paclitaxel, Topotecan, Gemcitabine
- Biological · Drug
- Lead sponsor
- Mural Oncology, Inc
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 456 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 31 more
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Interventions
- carboplatin
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Ovarian Cancer
- Interventions
- DCE-MRI scans
- Procedure
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Polycystic Ovary Syndrome
- Interventions
- Acupuncture, Sham Acupuncture
- Procedure
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years to 43 Years · Female only
- Enrollment
- 78 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Advance Care Planning
- Interventions
- video, usual care
- Behavioral
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 99 Years · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Ovarian Cancer
- Interventions
- Dexamethasone, Placebo
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 59 Years · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2013
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Ovarian Cancer
- Interventions
- carboplatin, cyclophosphamide, mitoxantrone hydrochloride, autologous bone marrow transplantation, bone marrow ablation with stem cell support
- Drug · Procedure
- Lead sponsor
- Loyola University
- Other
- Eligibility
- Up to 64 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1991 – 2005
- U.S. locations
- 1
- States / cities
- Maywood, Illinois
- Conditions
- Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4, Advanced Breast Cancer, Advanced Lung Carcinoma, NSCLC, NSCLC, Recurrent, NSCLC Stage IV, Relapsed Cancer, Relapse/Recurrence, Recurrent Breast Cancer, Recurrent NSCLC, Platinum-resistant Ovarian Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Endometrioid Tumor, High Grade Serous Carcinoma, Ovarian Epithelial Cancer
- Interventions
- Not listed
- Lead sponsor
- Lyell Immunopharma, Inc.
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Rocky Mount, North Carolina
- Conditions
- Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Teratoma, Testicular Germ Cell Tumor
- Interventions
- filgrastim, carboplatin, etoposide, ifosfamide, paclitaxel, autologous bone marrow transplantation, bone marrow ablation with stem cell support
- Biological · Drug · Procedure
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 16 Years to 120 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2014
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy
- Interventions
- Olaparib 300mg tablets, Placebo to match olaparib 300mg
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years · Female only
- Enrollment
- 327 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2026
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 11 more
- Conditions
- Cancer
- Interventions
- itraconazole, voriconazole
- Drug
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 12 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- Los Angeles, California